What is the Biomarkers for Rare Non-Oncological Diseases Summit?

The 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology.

Tackling critical challenges from early research through to late-stage market access, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need.

How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products?

Drawing on a multitude of disease areas spanning neurology, cardiology, metabolic, renal, inflammatory and more, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities.

With 2 days of in-depth case studies, interactive panel discussions, dedicated Q+A time and valuable networking opportunities, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory, payer and commercial discussions.

Take a look at the full event guide to see all case studies, pre-conference workshop details and the full expert speaker faculty!

Why Should You Attend?

Improving early validation, patient selection, clinical utility demonstration and reducing diagnostic timelines is critical to closing the gap on unmet clinical need for defined patient groups.

Built exclusively for biopharma, researchers and diagnostic developers, this meeting focuses specifically on the advancement of precision medicine in rare and defined patient groups. You can join fellow discovery, translational, clinical and commercial teams all dedicated to tackling the field’s most pressing challenges to radically improve patient outcomes and quality of care.

Hear What Our Attendees Say

“A conference focused on leveraging the ability of biomarkers and diagnostics to improve patient centricity in non-oncologic diseases was overdue, so kudos to Hanson-Wade for pulling together this inaugural event. I look forward to tracking progress in the field when I attend next year's sequel.”


“Excellent meeting, particularly the networking opportunities.”
Goldfinch Biopharma


“The meeting was very informative. The talks were all good and the chance to network was appreciated.”
PTC Therapeutics

2020 Partners


Other Events in the Series